Patents Assigned to ONO Pharmaceutical Co., Ltd.
  • Trk-INHIBITING COMPOUND
    Publication number: 20190231777
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Application
    Filed: April 5, 2019
    Publication date: August 1, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun TAKEUCHI, Satoshi ITADANI, Kazuya HASHIMURA, Masahiro IKURA, Masato HIGASHINO, Tetsuya YASUHIRO, Takeshi NAGAURA
  • Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
    Patent number: 10336741
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 2, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 10314844
    Abstract: Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 11, 2019
    Assignees: GILEAD SCIENCES, INC., ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seung H. Lee, Shingo Yamamoto
  • PURINONE DERIVATIVE
    Publication number: 20190169192
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Trk-inhibiting compound
    Patent number: 10300060
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 28, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura
  • Methods of producing anamorelin hydrochloride having controlled chloride content
    Patent number: 10300105
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 28, 2019
    Assignees: ONO PHARMACEUTICAL CO., LTD, HELSINN HEALTHCARE SA
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
  • QUINOLINE DERIVATIVE
    Publication number: 20190135785
    Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases
    Type: Application
    Filed: December 31, 2018
    Publication date: May 9, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
  • CRYSTAL POLYMORPHISM OF KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20190135755
    Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
  • METHOD FOR TREATING BRAIN TUMORS
    Publication number: 20190125720
    Abstract: Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2?R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1?-cyclopropan]-2?-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Applicants: ONO PHARMACEUTICAL CO., LTD., The Regents of The University of California
    Inventors: Hideho Okada, Tohru Kotani, Kazuhiko Takeda
  • KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20190127320
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
  • BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
    Publication number: 20190111019
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • DRUG FOR CANCER THERAPY CHARACTERIZED IN THAT AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR ARE ADMINISTERED IN COMBINATION
    Publication number: 20190099413
    Abstract: A drug for cancer therapy characterized in that an Axl inhibitor and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody) are administered in combination, wherein the Axl inhibitor is a compound represented by the general formula (I): (wherein in the formula, all of the symbols have the same meanings as defined in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, and the combination exhibits a strong anti-tumor effect and, therefore, is useful for cancer therapy.
    Type: Application
    Filed: February 24, 2017
    Publication date: April 4, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kohei TANAKA, Tomoko YASUHIRO
  • Process for producing purinone derivative
    Patent number: 10239879
    Abstract: According to the present invention, differently from well-known production methods, with the use of a different starting material, Ullmann condensation which may decrease the yield with an increase of a production scale can be avoided and thus 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one can be provided safely and stably with high reaction yield.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: March 26, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryo Suzuki, Atsushi Hiramatsu, Motoaki Tateyama, Hideyuki Sasahara
  • Purinone derivative
    Patent number: 10233185
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 19, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
    Patent number: 10214540
    Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 26, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Tatsuya Komagata, Takuya Nishio
  • PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20190054091
    Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 21, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshio YOSHIZAWA, Ryohei KOZAKI
  • Quinoline derivative
    Patent number: 10208022
    Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: February 19, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
  • Quinoline derivative
    Patent number: 10208034
    Abstract: A compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity, and therefore the compound can be an agent for treating Axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: February 19, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
  • Bicyclic compound and use thereof for medical purposes
    Patent number: 10201520
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 12, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • KCNQ2-5 channel activator
    Patent number: 10196358
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: February 5, 2019
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito